CHMP recommends EU marketing authorization for ARS Pharma's epinephrine nasal spray EURneffy

ARS Pharmaceuticals, Inc.

CHMP adopted positive opinion for EURneffy (2 mg epinephrine nasal spray) for emergency anaphylaxis treatment.
Indicated for adults and children ≥30 kg; EC decision expected within 67 days of June 27, 2024.
EURneffy is a needle-free alternative to injectable epinephrine, potentially expanding treatment access.
Corporate presentation updated for investor meetings; no financial guidance changes reported.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.